liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
Karolinska University Hospital.
Linköping University, Department of Medical and Health Sciences, Pulmonary Medicine. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Faculty of Health Sciences.
Karolinska University Hospital.
Show others and affiliations
2008 (English)In: Anticancer Research, ISSN 0250-7005, Vol. 28, no 5B, 2851-2857 p.Article in journal (Refereed) Published
Abstract [en]

Aim: To evaluate weekly, induction chemotherapy followed by weekly concomitant chemoradiotherapy in a multicentre phase II study of patients with wiresectable stage III non-small cell lung cancer (NSCLC; stage wet IIIB excluded). Patients (aid Methods: Eligible patients received three weekly cycles of paclitaxel 100 mg/m(2) and carboplatin AUC2 followed by six weekly cycles of paclitaxel 60 mg/m(2) and carboplatin AUC2 in combination with thoracic radiotherapy (2 Gy per fraction and day to a total (lose of 60 Gy), Results: Sixty-four patients (40 males and 24 females) with a median age of 63 Years (range, 43-79 years) entered the study. T and N stage were distributed as follows: T1 2 patients (3.2%). T2 10 patients (15.6%), T3 15 patients (23.4%). T4 37 patients (57.8%), N0 10 patients (15.6%). N1 1 patient (1.6%), N2 26 patients (40.6%), N3 26 patients (40.6%), and N missing I patient (1.6%). Seven patients (10.9%) suffered from grade 314 oesophagitis. Grade 112 oesophagitis occurred in 36 patients (56.3%) and pneumonitis grade 112 occurred in 10 patients (15.6%). Sixty-three patients were evaluated on an intent-to-treat basis. The overall response rate was 74.6%. The median time to progression was 247 days and median overall survival was 461 days. According to subgroup analyses, no statistically signicant differences were noted according to gender, age (<65 vs. >= 65 years), perfromance status, histology, or study centre. Conclusion: Induction chemotherapy followed by concurrent chemoradiotherapy with weekly cycles of paclitaxel and carboplatin is feasible and generates moderate toxicity. Efficacy is comparable to other recently published regimens. However, prognosis remains, ill general, poor for this group of patients and further work to develop better therapy is required.

Place, publisher, year, edition, pages
2008. Vol. 28, no 5B, 2851-2857 p.
Keyword [en]
Non-small cell lung cancer, phase II study, induction chemotherapy, paclitaxel, carboplatin, chemoradiotherapy
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-16190OAI: diva2:133401
Available from: 2009-01-09 Created: 2009-01-09 Last updated: 2014-01-14

Open Access in DiVA

No full text

Other links

Link to Article

Search in DiVA

By author/editor
Sederholm, ChristerKlintenberg, Claes
By organisation
Pulmonary MedicineFaculty of Health SciencesOncology
In the same journal
Anticancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 62 hits
ReferencesLink to record
Permanent link

Direct link